KARPAS-422
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
Karpas-422 is a B-cell non-Hodgkin’s lymphoma (NHL) cell line established from the pleural effusion of a patient with chemotherapy-resistant NHL. It has both t(14;18) and t(4;11) chromosomal translocations. Karpas-422 displays characteristics of a mature B-cell neoplasm in terms of both phenotype and genotype without any indications of commitment to other cellular lineages. The immunophenotype of Karpas-422 contains a strong expression of CD19, CD37, surface Ig, predominantly IgM and IgG, a weak expression of CD10, and no detection of CD5. Karpas-422 has a unique feature among lymphoid cell lines in that it expresses abundant CAMPATH-1 (CDw52) antigen at the surface. Karpas-422 cells can be cultured in RPMI1640 medium with 10% FBS and incubated at 37 °C in a humidified atmosphere containing 5% CO2.
Why choose Karpas-422 from AcceGen?
Karpas-422 from AcceGen are prepared and cryopreserved under rigorous and standardized conditions. All Karpas-422 cell products are prepared by our professional technicians, who have the rich experience in cell culture. Before delivery, our Karpas-422 cells have undergone comprehensive assessments to ensure the best growth performance, making them a reliable tool for customer use.
| Product Code | KARPAS-422; Karpas 422; KARPAS 422; Karpas422; KARPAS422; K422 |
| Species | Human |
| Cat.No | ABC-TC475S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphoblast |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lymphoma Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
Using Karpas-422, researchers can analyze the gene expression profiles of the lymphoma cell line in microarray assay and identify the aberration to produce malignant lymphoma. 
The t(14;18) chromosomal translocation in NHL cells can commonly induce over-expression of the anti-apoptotic protein BCL-2, resulting in increased cell survival, but it’s not sufficient to promote malignant lymphoma. Thus, further investigation using Karpas-422 could identify other additional genes as new targets for diagnostic refinement and novel therapeutic approaches.
